Loading...
•
Dec 31, 2025
Rxsight Q4 2025 Earnings Report
Rxsight Q4 2025 Earnings Report
Key Takeaways
RxSight reported a challenging fourth quarter with total revenue declining 19% year-over-year to $32.6 million, primarily driven by a significant 72% drop in Light Delivery Device (LDD) sales. Despite the revenue contraction, the company achieved a record gross margin of 77.5% due to a favorable product mix shift toward Light Adjustable Lenses (LAL), and sequential LAL unit growth of 10% suggests stabilizing demand.
Total revenue decreased 19% to $32.6 million, missing the prior year's record LDD placement levels.
Gross margin expanded significantly to 77.5%, up from 71.6% in Q4 2024, due to higher-margin LAL sales.
LAL unit sales showed sequential recovery, growing 10% over Q3 2025 despite a slight 2% year-over-year decline.
The company maintained a strong liquidity position with $228.1 million in cash and short-term investments.
Revenue by Segment
Forward Guidance
RxSight issued 2026 full-year guidance reflecting a transition year with lower LDD placements impacting both top-line growth and manufacturing efficiencies.
Positive Outlook
- Full year 2026 revenue projected up to $135 million.
- Continued expansion into international markets including Australia.
- Commercial initiatives from late 2025 showing early signs of progress.
- Strong cash position to fund strategic investments.
- Publication of superior clinical outcomes supporting LAL adoption.
Challenges Ahead
- Anticipated lower year-over-year LDD placements.
- Gross margin expected to compress to 70%-72% due to lower LDD production volumes.
- Operating expenses projected to remain high at $150M-$160M.
- Higher per-unit manufacturing costs expected in 2026.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...